In a randomized trial, FMT delivery by capsules was as effective as administration by colonoscopy.
Recurrent Clostridium difficile infection (RCDI) can be successfully treated by fecal microbiota transplantation (FMT). In a previous trial, FMT by nasogastric administration appeared to be as effective as delivery by colonoscopy in treating RCDI (NEJM JW Infect Dis Jun 2014 and Clin Infect Dis 2014; 58:1515).
Investigators have now conducted a noninferiority, randomized trial to compare the efficacy of administering FMT by oral capsules versus colonoscopy in preventing RCDI. A total of 116 participants with three or more episodes of CDI received FMT by capsule (40 pills) or colonoscopy (360 mL of fecal slurry in the cecum).
In the per-protocol analysis, prevention of RCDI was achieved in 96% of participants in both groups after a single FMT.…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)